NEW INDICATIONS

Lenvima plus Keytruda a New Combination Approved for Advanced Renal-Cell Carcinoma

JHOP - October 2021 Vol 11, No 5 - FDA Oncology Update
Download PDF

On August 10, 2021, the FDA accelerated the approval of the combination of lenvatinib (Lenvima; Eisai) and pembrolizumab (Keytruda; Merck) for the first-line treatment of adults with advanced renal-cell carcinoma (RCC). This combination received a breakthrough therapy designation for this indication.

This approval was based on the CLEAR study, a multicenter, open-label, randomized phase 3 clinical trial in patients with advanced RCC. The study included 355 patients who received lenvatinib plus pembrolizumab versus 357 who received single-agent sunitinib.

The primary end points were progression-free survival (PFS) and overall survival (OS). The median PFS was 23.9 months with the combination versus 9.2 months with sunitinib (P <.0001). The median OS was not reached in either arm. The objective response rate was 71% with the combination, including 16% complete responses, versus 36% (P <.0001) with sunitinib, including 4% complete responses.

Arterial thrombotic events occurred in 5% of patients in the CLEAR study, including myocardial infarction (3.4%) and cerebrovascular accident (2.3%).

Related Items
FDA-Approved Nirogacestat Demonstrates Improved Patient Outcomes in Desmoid Tumor Management
Web Exclusives published on February 12, 2024 in FDA Oncology Update
Iwilfin FDA Approved for Adults and Pediatric Patients with High-Risk Neuroblastoma
Web Exclusives published on January 17, 2024 in FDA Oncology Update
Welireg Now FDA Approved for Patients with Advanced Renal Cell Carcinoma
Web Exclusives published on January 17, 2024 in FDA Oncology Update
Keytruda Plus Chemotherapy Receives New FDA Approvals for Advanced Biliary Tract Cancer and 2 Forms of Advanced Gastroesophageal Junction Adenocarcinoma
Web Exclusives published on December 19, 2023 in FDA Oncology Update
FDA Approved Loqtorzi, a PD-1 Inhibitor, for the Treatment of Adults With Metastatic or Recurrent Nasopharyngeal Carcinoma
Web Exclusives published on December 18, 2023 in FDA Oncology Update
Tibsovo FDA Approved for Patients With Relapsed Myelodysplastic Syndromes and IDH1 Mutation
Web Exclusives published on December 18, 2023 in FDA Oncology Update
Fruzaqla FDA Approved for Refractory Metastatic Colorectal Cancer
JHOP - December 2023 Vol 13, No 6 published on December 6, 2023 in FDA Oncology Update
Rozlytrek Now Approved for Pediatric Patients Older Than 1 Month With Solid Tumors and NTRK Gene Fusion and in New Oral Pellet Form
JHOP - December 2023 Vol 13, No 6 published on December 6, 2023 in FDA Oncology Update
FDA Authorizes Updated COVID-19 Vaccine Formulations for Better Protection Against Current Variants
JHOP - December 2023 Vol 13, No 6 published on November 17, 2023 in FDA Oncology Update
Bosulif Now FDA Approved for Pediatric Patients With Chronic Myelogenous Leukemia
JHOP - December 2023 Vol 13, No 6 published on November 3, 2023 in FDA Oncology Update
© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: